Investigating OOS for Finished Product on the Stability Program. Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
|
|
- Oswald Silas Holmes
- 6 years ago
- Views:
Transcription
1 Investigating OOS for Finished Product on the Stability Program Presented by: Nicole Chang, QA Manager, Apotex Pty Ltd
2 Overview 1. Requirements of the commercial stability program 2. Out of Specification and atypical results 3. Phases of investigation Phase I: Laboratory investigation Phase II: Full scale investigation Phase III: Review of product development 4. Health Hazard Assessment 5. Assessing the Impact of OOS/OOT 6. Monitoring and Effectiveness Check 7. Testing to Proactively Identify Issues 8. Conclusion
3 Requirements of the Commercial Stability Program Medicinal Products The program should permit the detection of any stability issues associated with the formulation in the marketed package. The purpose of the program is to monitor the product over its shelflife and to determine that the product remains and can be expected to remain, within specifications under the labelled storage conditions. 1 batch per year, in every strength & every primary packaging type The principle of bracketing may be applied if scientifically justified & recorded Should be considered for any reworking, reprocessing or recovery operation. Out of specification or significant atypical trends should be investigated. Any confirmed OOS result or significant negative trend should be reported to the relevant competent authorities.
4 Out of Specification & Atypical Results Out of specification (OOS): Any result that falls outside of the registered specification. Ex. Assay result = 94.6%. Limit: %. Atypical result (i.e. OOT) Any result that is within the registered limit, but appears irregular or outside the trend of previous results. Or routine trending shows that it will not meet specification at expiry. OOS/OOT within a stability study This issue is more complex than an OOS within release Product on the market could be affected This may lead to a recall % Ass say Months (expiry = 24)
5 Phase I: Laboratory Investigation Upon observation of an OOS/OOT result, the Analyst should immediately inform the Supervisor. Together, they should determine if an assignable cause for the result exists by reviewing the following: Raw data Review chromatograms and print outs Compare results to historical data or trends Sample Was the correct sample tested? considerations Is there evidence of contamination or improper sample appearance, storage, handling, labelling or damage. Inspect the sample in the original container and all sample preparations to determine if samples have been compromised or may not have been fully extracted Equipment Was the correct equipment used and were the settings correct? Are there any indications of equipment malfunction? Is the calibration/maintenance current? Were system suitability parameters met? Test execution & analyst training Was the correct method used? Was the raw data properly documented? Was the analyst trained on the technique? Standard & sample preparations Review other test results within the run Check the standards, solvents and reagents to determine if they are correct and have been preconditioned properly Were correct standards/chemicals used? Was the sample powder homogenous? Were all solutions prepared correctly? Are the results acceptable? Is there a clear bias to the run?
6 Phase I: Laboratory Investigation Party Responsibilities Analyst Achieve accurate laboratory testing results Ensure that only those instruments meeting established performance specifications are used and that all instruments are properly calibrated Ensure system suitability requirements are met Check data for compliance to test specifications prior to discarding of sample preparations Immediately document any deviations that have occurred during testing (i.e. spills, incomplete transfer of sample composite, OOS/OOT) Supervisor Contract Laboratory Manufacturer s QCU Provide an objective and timely assessment once an OOS has been identified Convey its data, findings and supporting documentation to the manufacturing firm s quality control unit (QCU) Initiate full scale OOS investigation
7 Phase II: Full Scale Investigation Review Production Records Perform complete review of batch records for the impacted batch and identify the following: Dates manufacturing, packaging, expiry and stability study initiation Any deviations issued during manufacturing or packaging Raw material batches used in the manufacturing of the impacted batch including capsule shells for encapsulated product. Consider other batches that may have used those materials. Compare these results/parameters to other released batches of the product. In process testing results. E.g. hardness, thickness, average weight, and if applicable disintegration, LOD, release testing of intermediates Production parameters, e.g. compression/encapsulation speed, coating. Any process or formulation changes including new excipient or raw material suppliers.
8 Phase II: Full Scale Investigation Review Stability Data Review the stability data for the impacted batch and for the product. Make note of any relevant trends. Confirm if there was any previous laboratory investigations or OOT results Review forced degradation or accelerated stability data to determine stability of the product under stress conditions. Confirm and summarize if there are any previous stability OOS or OOT events for the batch and/or product. Consider all stability study types (i.e. conditions, pack format, etc.) Review complaint/ade history for the batch and product Identify any reports that may be related to the investigation.
9 Phase III: Review of Product Development May be necessary when further evaluation is required to be performed on the formulation, method or if additional studies are required. Studies may be required to isolate, identify and qualify impurities Change and re-validation of analytical methods may be required Changes to specifications may be necessary based on evaluation of the stability data Widening of specifications Tightening of release specifications Proposal for changes in the container closure system may be necessary if there is a reaction of the product with components of the container closure system. Proposal for changes in the formulation of the product or termination of the formulation if instability of the product is related to the formulation. Note: Changes listed above may require TGA approval in order to implement.
10 Health Hazard Assessment Responsibilities of sponsors All sponsors of products must ensure that it has an appropriate system of pharmacovigilance (PV) in place in order to assure responsibility and liability for its products on the market and to ensure that appropriate action can be taken when necessary. A sponsor should have a permanent and qualified person for PV who has experience in all aspects of PV and if not medically qualified should report or have access to a medically qualified person. The following information is required in order to make a proper assessment: Thorough description of the problem Clear identification of the impurity, if relevant. Quantitative estimate of the levels of active, impurity, etc.
11 Health Hazard Assessment (cont d) The assessment should consider the following: Have any illnesses or injury resulted from the use of the product? What population is most affected by this hazard? How serious is the health hazard? How likely will illness be the result of this hazard? Are the consequences from this hazard short or long term? Assessments should conclude if the impact of the OOS/OOT to the patient is: Potentially life-threatening or could cause serious risk to health (Class I) Could cause illness or mistreatment (Class II) Non safety related (Class III)
12 Assessing the Impact of OOS/OOT Upon confirmation of an OOS or OOT result, determine the impact to marketed products. Identify all impacted customers Block remaining inventory if there is evidence to suggest that the OOS result is isolated to the specific batch or the product. Consider whether there is a common active raw material or common blend. If there is evidence to suggest that the OOS result obtained is related to issues with formulation, process or packaging, consider placing production/packaging documents on hold to prevent further production Perform a health hazard assessment (for safety/efficacy), if applicable Perform risk assessment and provide proposal(s) to the relevant authorities Ensure timely investigation and set targets for completion.
13 Post Monitoring & Effectiveness Check Once the investigation has been completed consider: Continue reviewing reports of ADEs and LOEs for the impact batch/product. Review stability data for other batches of the impacted product. If changes to the product/packaging were required as a result of the investigation, review stability of post-change batches to confirm that the change is effective. Monitor batches under worse case conditions. If no cause was determined for the OOS/OOT, consider additional time point testing within or after expiry or initiation of worse case studies.
14 Testing to Proactively Identify Issues Worse case testing should be considered to identify any issues with the stability. Involves: Storage of samples under relevant climatic conditions (i.e. long-term: 25 & 30 C.) Only the sample stored under stricter conditions is analysed (thus covers the lower conditions) In case of OOS results, the sample stored under lower conditions will be analysed too. Example: Protocol for product labelled as, Store below 25 C. Testing under accelerated conditions should be considered for: validation batches, after a major change to the process/formulation/packaging.
15 Conclusions Ensure that you have the following procedures in place: Laboratory investigation Full scale investigation Health Hazard Assessment Post monitoring and effectiveness check Good practice to store and test samples under the worse case condition. Consider initiating accelerated studies for batches where there have been major changes to the process/formulation/packaging Routine trending is necessary to proactively identify any potential failures. Any confirmed OOS, or significant negative trends should be reported to the competent authorities
16 Relevant Standards & Guidance Documents PIC/S Guide for Good Manufacturing Practice for Medicinal Products,15 Jan 2009 ICH Q9 Quality Risk Management, 9 Nov, 2005 Uniform recall procedure for therapeutic goods (URPTG), 2004 edition Guidance for Industry - Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, U.S. Dept of Health & Human Services, Food & Drug Administration Centre for Drug Evaluation and Research (CDER), Oct 2006 ICH Q1A(R2) Stability Testing of new Drug Substances and Products, Aug 2003
17 Thank you! QUESTIONS?
Laboratory OOS Investigations The Missing Link
Laboratory OOS Investigations The Missing Link India Pharmaceutical Alliance Carmelo Rosa, Psy.D Director Division of Drug Quality I November 6-17, 2017 Indian Pharmaceutical Alliance DISCLAIMER: The views
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationGuidance for Industry
Guidance for Industry Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationValidation of Pharmaceutical Manufacturing Process Focus: APIs.
Validation of Pharmaceutical Manufacturing Process Focus: APIs Validations: Regulatory History (US FDA) Sterilisation 1977 Aseptic processing 1979 Water Systems 1981 Non-sterile Mfg Process 1987 Revised
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationGood Manufacturing Practices Purpose and Principles of GMP. Tony Gould
Good Manufacturing Practices Purpose and Principles of GMP Tony Gould Why GMP? Provides a high level assurance that medicines are manufactured in a way that ensures their safety, efficacy and quality Medicines
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationINVESTIGATE OOT AND OOS IN STABILITY STUDIES
INVESTIGATE OOT AND OOS IN STABILITY STUDIES Kim Huynh-Ba Executive Director Pharmalytik LLC www.pharmalytik.com BIOGRAPHY Kim Huynh-Ba has over 25 years of experience in analytical development, project
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer
Prequalification Team WHO PUBLIC INSPECTION REPORT (WHOPIR) Active Pharmaceutical Ingredient (API) Manufacturer PART 1: GENERAL INFORMATION Name of Manufacturer Calyx Chemicals & Pharmaceuticals Ltd Unit:
More informationManual 058 Out of Specification Results Investigation
1 Purpose The purpose of this Guideline is to provide guidance for the investigation and response to Out of Specification (OOS) laboratory test results. 2 Scope and Applicability This Guideline applies
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationEudraLex. Part I1 Chapter 6: Quality Control
EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines tofor Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use Part I1 Chapter 6: Quality
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationHandling OOS, OOT and Unexpected Results. Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017
Handling OOS, OOT and Unexpected Results Karen Ginsbury PCI Pharmaceutical Consulting Israel Ltd for IFF, October 2017 What is an OOS What is an OOT What is an Unusual, Questionable, Atypical Result Objective:
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationCERTIFIED MAIL RETURN RECEIPT REQUESTED
Department of Health and Human Services Public Health Service Food and Drug Administration Warning Letter WL: 320-14-11 CERTIFIED MAIL RETURN RECEIPT REQUESTED June 16, 2014 Jeremy B. Desai, PhD President
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More informationDocumenta tion and Records
Documenta tion and Records Page 1 of 30 Training Outcome of the Module: After completing this module, you will be able to: Recognize the importance of procedures Recognize the importance of record keeping
More informationReview article Rapports De Pharmacie 2015;1(2):46-53 ISSN:
Review article Rapports De Pharmacie 2015;1(2):46-53 ISSN: 2455-0507 ABSTRACT APPLICATION OF RISK ASSESSMENT IN PRODUCT QUALITY LIFECYCLE MANAGEMENT Subin Sankarankutty Regulatory Consultant, Health Sciences
More informationFOOD AND DRUGS AUTHORITY
G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationDECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW
DECEMBER 2008 GUIDANCE NOTES ON PRODUCT QUALITY REVIEW 1.0 INTRODUCTION: The purpose of this guidance is to communicate the expectation with regard to the conduct of Product Quality Review. Product Quality
More informationPage 1 of 5 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More informationOut of Specification & Out of Trend Investigations. October 2017
Out of Specification & Out of Trend Investigations October 2017 How to use the Investigation Flowchart Navigation: Clicking on those Process Step boxes with a heavy border in a process flow will take you
More informationTechnical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable
Technical requirements to Good Manufacturing Practice in metered dose inhalers production and development (2. part) Extractable - Leachable Dr. Gyula Körtvélyessy UNIDO Honorary Secretary General of the
More informationANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX V ASEAN GUIDELINES ON STABILITY STUDY AND SHELF-LIFE OF HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationGMP Track 1 Day 2 Session 1 Vendor Assurance
GMP Track 1 Day 2 Session 1 Vendor Assurance 11 August 2015 150403_POUT This session Three presentations Chapter 6 and 7 - Trevor Schoerie Quality Control Out sourced Activities Draft - FDA Quality Metrics
More informationQ&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document
Q&A on ICH Q7 Good Manufacturing Practice Questions and Answers Document March 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 ICH Q7 - Questions
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationDr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur
Dr. Sheelpriya walde Professor Gurunanak college of pharmacy, Nagpur GMP ( Adopted in 1975 ) In India Good manufacturing practices are the practices required in order to conform to guidelines recommended
More informationEquipment cleaning and use record
DOCUMENTATION Documentation is an essential part of the quality assurance system and, as such, should be related to all aspects of GMP. Its aim is to define the specifications for all materials and the
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationPre-Approval Inspections for Drug Products
Pre-Approval Inspections for Drug Products FDA Small Business Regulatory Education for Industry Conference June 20, 2013 H.L. Jamillah Selby Consumer Safety Officer FDA, Dallas District Office Presentation
More informationMedicines Variations Guideline
Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationEssentials in Stability Analysis and Expiry Determination
Published in BioPharma International. Essentials in Stability Analysis and Expiry Determination Thomas A. Little Ph.D. 6/12/2013 President Thomas A. Little Consulting 12401 N Wildflower Lane Highland,
More informationGuidance for Industry Q3B(R2) Impurities in New Drug Products
Guidance for Industry Q3B(R2) Impurities in New Drug Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics
More informationPharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA
Pharmacist Rana Musa Al-ali (Malkawi) MSc (Pharmaceutical Quality Assurance) Registration Department/JFDA 1 2 ND MENA Regulatory Conference On Bioequivalence, Biowaivers, Bioanalysis, Dissolution & Biosimilars
More informationQuality Agreement. by and between. Supplier Name. Address: and. Client Name: Address:
NOTE TO USERS This Quality Agreement template was developed by the Bulk Pharmaceutical Task Force (BPTF), an affiliate organization of the Society of Chemical Manufacturers and Affiliates (SOCMA), as a
More informationPrequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer. Tablets
Prequalification Team Inspection services WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: information about the inspection Name of manufacturer Physical address production departments
More informationValidation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.
Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals. 1 Analytical Method Validation: 1..1 Philosophy: Method validation is
More informationPharmaceutical Good Manufacturing Practice. Contents are subject to change. For the latest updates visit
Pharmaceutical Good Manufacturing Practice Page 1 of 6 Why Attend A robust quality system that meets the requirements of pharmaceutical regulators is an essential element of every good pharmaceutical manufacturing
More informationRegulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017
Regulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017 Hugo Hamel, Senior Biologist/Evaluator, BGTD Overview of the Post-NOC Changes
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationPHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME. PI July 2018
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 045-1 1 July 2018 GUIDELINES ON THE FORMALISED RISK ASSESSMENT FOR ASCERTAINING THE APPROPRIATE GOOD MANUFACTURING
More informationMaterials Management Traceability, CEPs and managing non-conforming sites
Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain
More informationManual 055 Commercial Stability Testing For Formulated Products. This procedure applies to all drug products. The procedure covers:
1 Purpose Manual 055 Commercial Stability Testing For Formulated Products The intent of this procedure is to provide to manufacturing and primary packaging sites the principles of a stability program.
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationINTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Review Article
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Review Article INTRODUCTION AND GENERAL OVERVIEW OF PHARMACEUTICAL PROCESS VALIDATION: A REVIEW Pandita Rachna* 1, Rana A C
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationThe World Bank. Aide Memoire for use during GMP inspections
The World Bank e for use during GMP inspections The World Bank Procurement of Health Sector Goods Contact persons: 0 1. General information about the manufacturer Name of manufacturer Physical address
More informationQuality Agreements with CMO s. Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals
Quality Agreements with CMO s Presented at ASQ Orange Empire Meeting May 13, 2014 By Luke Foo Sr. Director QA/QC Spectrum Pharmaceuticals FDA Guidance Contract Manufacturing Arrangements for Drugs: Quality
More informationCommonly Seen Drug Product Related Quality Deficiencies
Commonly Seen Drug Product Related Quality Deficiencies 2016 GPhA CMC Workshop Bethesda, MD; May 18, 2016 Geoffrey Wu, PhD, CPH Lieutenant, US Public Health Service Associate Director for Science & Communication
More informationStage 3 - Process Validation: Measuring what matters
Stage 3 - Process Validation: Measuring what matters Trevor Schoerie - PharmOut A quote. The company that fails is the company that comes to us and says Just tell us what to do and we will do it. The company
More informationPrequalification of Medicines Programme
Prequalification of Medicines Programme SOP 408.4 Annex A WHO PUBLIC INSPECTION REPORT Finished Product Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) Finished Product Manufacturer Part 1: General
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT API Manufacturer WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer Part 1: General information Name of Manufacture Unit number
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationOOS: Back to Basics. Compliant, Effective, Efficient PATH
OOS: Back to Basics Even with the number of trainings, seminars, online webinars and consultant guided investigations, companies are still seeing FDA 483 observations around how they are handling and investigating
More informationICH Q3D. Questions & Answers Q1: Q2: U n d e r s ta n d i n g the Risk Assessment Requirements. Knowing the Options
ICH Q3D Questions & Answers Understanding the Risk Assessment Requirements Knowing the Options Controlling for Elemental Impurities Responsibilities U n d e r s ta n d i n g the Risk Assessment Requirements
More informationRegulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.
Regulatory Aspects of Cleaning and Cleaning Validation Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. 28 June 2017 Why clean? Pharmaceutical production equipment is cleaned
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationMethod Validation Studies How GLP Interacts With Guidance Documents
Method Validation Studies How GLP Interacts With Guidance Documents Steven S. Kuwahara ROBERT GEORGE YOUNG/GETTY IMAGES GLP Forum addresses topics of interest associated with good laboratory practices.
More informationAPI Stability Protocols and. Chris Byrne Tasmanian Alkaloids
API Stability Protocols and Evaluations Chris Byrne Tasmanian Alkaloids API Stability Overview APIs = 100% pure Limited (if any) degradation No interactions with other agents in drug products Less likelihood
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationPrequalification of Medicines Programme. WHO PUBLIC INSPECTION REPORT (WHOPIR) API Manufacturer
Prequalification of Medicines Programme SOP 408.4 Annex B WHO PUBLIC INSPECTION REPORT API Manufacturer Part 1: General information Name of Manufacturer Unit number WHO PUBLIC INSPECTION REPORT (WHOPIR)
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationNIRS, PAT, RTR testing EU experience and regulatory perspective
NIRS, PAT, RTR testing EU experience and regulatory perspective Heidelberg, Germany October 2013 European Compliance Academy (ECA) Overview of the presentation General considerations Cases submitted in
More informationGood Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED
Good Manufacturing Practice ( GMP ) Compliance: GMPs EXPLAINED Presented by Raymond A. Bonner Nathan C. Sheers SIDLEY AUSTIN BROWN & WOOD, LLP Washington, D.C. (202) 736-8000 To The Fourth Annual Pharmaceutical
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationTop Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp
Top Annual 483 Observations: The Cycle of Quality June 2017 Presented by: Susan Schniepp 2016 Regulatory Compliance Associates Inc. Top Observation for 5 years Year Drugs #1 citation Device #1 citation
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationInt. J. Pharm. Sci. Rev. Res., 34(1), September October 2015; Article No. 23, Pages: Process Validation of Tablet Dosage Form in Industries
Review Article Process Validation of Tablet Dosage Form in Industries Ram Mohan S.R, N. Vishal Gupta* Pharmaceutical Quality Assurance group, Dept of Pharmaceutics, JSS University, Sri ShivarathreeshwaraNagara,
More informationTHE NEW QUALITY PARADIGM OPPORTUNITIES AND EXPECTATIONS IN ICH Q8 Q9 Q10 Q11 DR. FRITZ ERNI
THE NEW QUALITY PARADIGM IN ICH Q8 Q9 Q10 Q11 OPPORTUNITIES AND EXPECTATIONS DR. FRITZ ERNI FRITZ@ERNI.NET THE NEW PARADIGM OR QUALITY BY DESIGN Why do we need it! Some background Information The impact
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationImplementing Continuous Pharmaceutical Manufacturing: An FDA Perspective
Implementing Continuous Pharmaceutical Manufacturing: An FDA Perspective Christina Capacci-Daniel, Ph.D. Acting Quality Assessment Lead / Consumer Safety Officer Division of Inspectional Assessment, Office
More informationWARNING LETTER CMS #
U.S. Food and Drug Administration Division of Pharmaceutical Quality Operations I 10 Waterview Blvd 3rd FL, Parsippany NJ 07054 Telephone: (973) 331-4900 Fax: (973) 331-4969 www.fda.gov Via UPS Next Day
More informationASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group
ASMF/DMF Quality Assessment Report (QAR) IGDRP Quality Working Group Version Description of Change Author Effective Date v 1.0 Original publication ASMF/DMF WG May 26, 2015 v 1.1 Watermark added ASMF/DMF
More informationDrug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel
Drug Quality Assurance: Systems at ChemCon Author: Dr. Peter Gockel On February 13th, 2006, the FOOD AND DRUG ADMINISTRATION (FDA) implemented a revision to the Compliance Program Guidance Manual for active
More information